• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's After-Market Session

    1/19/24 4:31:09 PM ET
    $ADIL
    $AFIB
    $BCEL
    $BIOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $ADIL alert in real time by email

    Gainers

    • Talphera (NASDAQ:TLPH) stock increased by 10.2% to $0.97 during Friday's after-market session. The company's market cap stands at $16.4 million.
    • Biora Therapeutics (NASDAQ:BIOR) shares increased by 8.55% to $0.99. The market value of their outstanding shares is at $26.9 million.
    • Vanda Pharma (NASDAQ:VNDA) shares rose 4.91% to $3.84. The company's market cap stands at $220.9 million.
    • Unity Biotechnology (NASDAQ:UBX) stock moved upwards by 4.79% to $1.75. The company's market cap stands at $29.3 million.
    • Adial Pharmaceuticals (NASDAQ:ADIL) shares moved upwards by 4.54% to $1.38. The market value of their outstanding shares is at $1.6 million.
    • Alaunos Therapeutics (NASDAQ:TCRT) shares increased by 4.48% to $0.12. The market value of their outstanding shares is at $29.7 million.

    Losers

    • Atreca (NASDAQ:BCEL) stock fell 9.6% to $0.27 during Friday's after-market session. The market value of their outstanding shares is at $10.7 million.
    • Windtree Therapeutics (NASDAQ:WINT) stock decreased by 6.19% to $0.47. The company's market cap stands at $2.4 million.
    • Fusion Pharmaceuticals (NASDAQ:FUSN) shares fell 6.04% to $8.57. The company's market cap stands at $620.5 million.
    • Elicio Therapeutics (NASDAQ:ELTX) stock declined by 5.53% to $4.43. The market value of their outstanding shares is at $42.5 million.
    • Shattuck Labs (NASDAQ:STTK) shares fell 4.99% to $8.57. The company's market cap stands at $364.1 million.
    • Acutus Medical (NASDAQ:AFIB) stock decreased by 4.98% to $0.17. The company's market cap stands at $4.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADIL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADIL
    $AFIB
    $BCEL
    $BIOR

    CompanyDatePrice TargetRatingAnalyst
    Elicio Therapeutics Inc.
    $ELTX
    3/10/2026$17.00Buy
    Rodman & Renshaw
    Shattuck Labs Inc.
    $STTK
    3/6/2026$25.00Buy
    Needham
    Vanda Pharmaceuticals Inc.
    $VNDA
    3/5/2026$18.00Buy
    Truist
    Shattuck Labs Inc.
    $STTK
    1/28/2026$15.00Overweight
    Piper Sandler
    Shattuck Labs Inc.
    $STTK
    12/1/2025$6.00Neutral → Buy
    H.C. Wainwright
    Vanda Pharmaceuticals Inc.
    $VNDA
    11/5/2025$11.00Buy
    B. Riley Securities
    Shattuck Labs Inc.
    $STTK
    9/8/2025$4.00Outperform
    Wedbush
    Unity Biotechnology Inc.
    $UBX
    5/27/2025$2.00Buy → Neutral
    H.C. Wainwright
    More analyst ratings

    $ADIL
    $AFIB
    $BCEL
    $BIOR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Orbimed Advisors Llc bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:52:10 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ashiya Mona bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:50:52 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Polymeropoulos Mihael Hristos bought $41,500 worth of shares (10,000 units at $4.15), increasing direct ownership by 0.43% to 2,335,731 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    8/8/25 4:05:18 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AFIB
    $BCEL
    $BIOR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for PONVORY issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

    6/17/24 12:07:18 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for FANAPT issued to VANDA PHARMS INC

    Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

    4/3/24 4:12:36 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AFIB
    $BCEL
    $BIOR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Vanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods

    WASHINGTON, March 19, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, today voiced serious concerns over the U.S. Food and Drug Administration (FDA)'s new draft guidance, "General Considerations for the Use of New Approach Methodologies in Drug Development," released March 18, 2026, by the Center for Drug Evaluation and Research (CDER). The FDA's draft guidance aims to support the use of New Approach Methodologies (NAMs)—advanced non-animal tools like in v

    3/19/26 4:34:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Reports Inducement Grants

    BOSTON, March 17, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on March 16, 2026, Elicio granted an aggregate of 1,600 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. The grant provides for the

    3/17/26 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates

    Event-driven primary disease-free survival ("DFS") analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma ("PDAC") is anticipated in 1H 2026Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial The Company remains blinded to the Phase 2 AMPLIFY-7P trial clinical efficacy outcomes.Projected cash runway into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 DFS analysis in 1H 2026 BOSTON, March 12, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of n

    3/12/26 4:05:00 PM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AFIB
    $BCEL
    $BIOR
    SEC Filings

    View All

    SEC Form EFFECT filed by Elicio Therapeutics Inc.

    EFFECT - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/17/26 12:15:11 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/16/26 9:19:42 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Elicio Therapeutics Inc.

    424B5 - Elicio Therapeutics, Inc. (0001601485) (Filer)

    3/16/26 9:18:38 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AFIB
    $BCEL
    $BIOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Elicio Therapeutics with a new price target

    Rodman & Renshaw initiated coverage of Elicio Therapeutics with a rating of Buy and set a new price target of $17.00

    3/10/26 8:40:26 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Needham resumed coverage on Shattuck Labs with a new price target

    Needham resumed coverage of Shattuck Labs with a rating of Buy and set a new price target of $25.00

    3/6/26 8:36:02 AM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Truist initiated coverage on Vanda Pharma with a new price target

    Truist initiated coverage of Vanda Pharma with a rating of Buy and set a new price target of $18.00

    3/5/26 8:32:16 AM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AFIB
    $BCEL
    $BIOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP & General Counsel Williams Timothy sold $350,755 worth of shares (42,434 units at $8.27), decreasing direct ownership by 10% to 377,450 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    3/4/26 6:54:11 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, CFO & Treasurer Moran Kevin Patrick sold $350,821 worth of shares (42,442 units at $8.27), decreasing direct ownership by 9% to 411,380 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    3/4/26 6:53:14 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Marketing Officer Wijkstrom Joakim sold $254,590 worth of shares (30,800 units at $8.27), decreasing direct ownership by 8% to 333,469 units (SEC Form 4)

    4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

    3/4/26 6:52:29 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AFIB
    $BCEL
    $BIOR
    Leadership Updates

    Live Leadership Updates

    View All

    Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer

    BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio" or the "Company")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Marc J. Wolfgang, M.S. as Chief Technology Officer ("CTO"). Mr. Wolfgang brings more than 30 years of biopharmaceutical leadership spanning manufacturing, CMC strategy, development, quality, and supply chain across modalities including cell therapy, biologics, nucleic-acid medicines, vaccines, and LNP platforms. He most recently served as Senior Vice President of Technical Development and Operations at Sail Biomedicines (a Flagship

    11/19/25 8:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Evofem Biosciences' CEO Saundra Pelletier Joins Aditxt Board of Directors

    Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) ("Evofem"), to Aditxt's Board of Directors. "We believe that Saundra's background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her contributions at this critical stage as we seek to execute our growth strategy for the overall business, transition Aditxt to a commercial stage company, and advance our plans to build a vertical focus on monitoring, prevention and treatment

    6/9/25 8:15:00 AM ET
    $ADTX
    $WINT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer

    BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (NASDAQ:ELTX, "Elicio Therapeutics" or "Elicio")), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced the appointment of Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, effective as of the date hereof. Dr. Shah brings a wealth of leadership experience to Elicio after previously serving as chief financial officer, chief business officer, and in other senior leadership roles at multiple publicly traded biotechnology companies. "We are pleased to welcome Preetam to Elicio's executive team," said Robert Connelly, Ph.D., Preside

    3/24/25 7:00:00 AM ET
    $ELTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADIL
    $AFIB
    $BCEL
    $BIOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Acutus Medical Inc.

    SC 13D/A - Acutus Medical, Inc. (0001522860) (Subject)

    12/16/24 9:52:56 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Windtree Therapeutics Inc.

    SC 13G/A - WINDTREE THERAPEUTICS INC /DE/ (0000946486) (Subject)

    11/14/24 7:15:44 PM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADIL
    $AFIB
    $BCEL
    $BIOR
    Financials

    Live finance-specific insights

    View All

    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

    Full year 2025 Fanapt® net product sales increased by 24% to $117.3 million compared to full year 2024Full year 2025 total revenues increased by 9% to $216.1 million compared to full year 2024NEREUS™ (tradipitant) approved for the prevention of vomiting induced by motionBysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia under review by the FDA; PDUFA target action date of February 21, 2026WASHINGTON, Feb. 11, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2025.

    2/11/26 4:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026

    Conference Call and Webcast to Follow WASHINGTON, Feb. 4, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced it will release results for the fourth quarter and full year 2025 on Wednesday, February 11, 2026, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 11, 2026, during which management will discuss the fourth quarter and full year 2025 financial results and other corporate activities. To participate in the conference call, please dial 1-888-596-4144 (domestic) or 1-646-968-2525 (international

    2/4/26 6:01:00 PM ET
    $VNDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates

    Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues) Windtree would receive a payment of $700,000 from Seismic Pharmaceutical Holdings contingent on a financing round resulting in gross cash proceeds of at least $10,000,000 Additionally, Windtree transfers certain cardiovascular development payables to Seismic Pharmaceutical Holdings WARRINGTON, Pa., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or "the Company") (OTCID: WINT), a diversified company with several divisions and focused on becoming

    12/23/25 9:00:00 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care